PuraPharm to Vote Oct. 24 on Rheumatoid Arthritis Drug License, Share Issue Agreements
MT Newswires Live
Oct 02
Shareholders of PuraPharm (HKG:1498) will meet Oct. 24 to vote on the firm obtaining an exclusive license for BN101E from a company controlled by its CEO and chairman Chan Yu Ling, a Thursday Hong Kong bourse filing said.
BN101E is being developed as an anti-inflammatory botanical drug for the treatment of rheumatoid arthritis.
The traditional Chinese medicine company will issue nearly 93.5 million, or HK$40.2 million worth of shares to settle the payment due to the licensor.
Shareholders will also vote on the issue of over 46.5 million shares at HK$0.43 apiece to Providence Capital Group to raise gross proceeds of HK$20 million. Proceeds will be used to advance research of BN101E.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.